Sorafenib Maintenance in Patients With FLT3-ITD AML Undergoing Allogeneic HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sorafenib Maintenance in Patients With FLT3-ITD Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: An Open-Label, Multicentre, Randomised Phase 3 Trial
Lancet Oncol 2020 Aug 10;[EPub Ahead of Print], L Xuan, Y Wang, F Huang, Z Fan, Y Xu, J Sun, N Xu, L Deng, X Li, X Liang, X Luo, P Shi, H Liu, Z Wang, L Jiang, C Yu, X Zhou, R Lin, Y Chen, S Tu, X Huang, Q LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.